top of page
  • Writer's pictureARQon

Drugs - May 2018

  • International - Press Release of the PIC/S Committee Meeting in Geneva (Switzerland), May-2018

  • Australia - Australian Regulatory Guidelines for Complementary Medicines (ARGCM)

  • China - Marketing Authorization Procedures: Procedure for Unapproved Drug Use / Compassionate Use

  • Japan - PMDA/AREDPG No. 0517001: Revision of Technical Conformance Guide on Electronic Study Data Submissions

  • Canada - Consultation for Mandatory Requirements of using Electronic Common Technical Document (eCTD) Format when Submitting Master Files (MFs)

  • European Union - CMDh/373/2018, Rev.0: Practical Guidance for Procedures Related to Brexit for Medicinal Products for Human Use Approved Via MRP/DCP

  • European Union - EMA/191104/2015: European Medicines Agency Guidance for Applicants Seeking Access to PRIME Scheme

  • United Kingdom - MHRA: Guidance for the Notification of Serious Breaches of Good Clinical Practice or the Trial Protocol

  • United Kingdom - SI 2018 No.345: The Branded Health Service Medicines (Costs) Regulations 2018, 08-Mar-2018 (and its Correction)

  • Brazil - Dissolution Methods Applicable to New, Generic and Similar Medicinal Products

  • Gulf Cooperation Council - GHC Circular 1837: Cancellation of Registered Products With Expiring Central Registration

  • Saudi Arabia - Sanctions Applicable to Manufacturers or their Authorized Representatives for Not Reporting Field Actions on Medical Products and Devices

  • USA - Federal Register Amendment: Removal of Certain Time of Inspection and Duties of Inspector Regulations for Biological Products; Withdrawal (Direct final rule; withdrawal)

  • USA - Draft Guidance for Industry: Waivers, Exceptions, and Exemptions from the Requirements of Section 582 of the Federal Food, Drug, and Cosmetic Act, May-2018

Contact us at info@arqon.com.


18 views0 comments

Recent Posts

See All

Europe - May 2020

Denmark: New rules mean non-serious adverse events may also need to be reported EU: Application of Regulation (EU) 2017/745 postponed by one year EU: Continued use of lead as a thermal stabiliser in P

EU: MDR delayed to 26 May 2021

Application of the Medical Devices Regulation (MDR) has been deferred by one year, until 26 May 2021, for fear of shortage or delay in getting essential medical devices needed to combat Covid-19. The

EU 2020 MDR Guidance Notes For Class I Manufacturers

There will be no transition period for Class I medical devices which remain in Class I under MDR. From 26th May 2020 onwards, the conformity for Class I medical devices which are not subject to up-cla

bottom of page